DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Metoprolol, 777
absortion, fate, and excretion
of, 326
adrenergic receptors and, 207t
for angina, 767
antiarrhythmic use of, 831
as antihypertensive agent, 774t
cardioprotective effects of, 767
pharmacokinetics of, 1863t
structure of, 311f
therapeutic uses of, 326–327
for myocardial ischemia, 767
Metrifonate, 1458
Metrizamide, 1153t
METROCREAM (metronidazole), 1817
METROGEL (metronidazole), 1817
Metronidazole
absorption, fate, and excretion of,
1429
antiparasitic and antimicrobial
effects of, 1428–1429
for bacterial vaginosis, 1842t
bioequivalency with, 23
contraindications to, 1430
drug interactions with, 1430
mechanism of action of, 1429
pharmacokinetics of, 1864t
resistance to, 1429
therapeutic uses of, 1429–1430
for inflammatory bowel disease,
1352t
topical, for acne, 1817
toxicity of, 1430
for trichomonas, 1842t
METVIXIA (methylaminolevulinate),
1815
Metyrapone, 1235–1236
Metyrosine, as antihypertensive agent,
783
MEVACOR (lovastatin), 897
Mevastatin, 893, 894
structure of, 893f
Mexiletine
antiarrhythmic use of, 828, 836t,
842
contraindications to, 833t
dosage of, 836t
electrophysiological actions of, 829t
pharmacokinetics of, 836t
structure of, 842
MEXITIL (mexiletine), 842
MEXORYL SX (ecamsule), 1827
Mezlocillin, 1484
chemistry of, 1479t
properties of, 1479t
Mianserin, potencies at human
transporters for monamine
neurotransmitters, 406t
Mibefradil, and statins, interactions,
896
Micafungin, 1584
pharmacokinetics of, 1864t
MICARDIS (telmisartan), 738
MICATIN (miconazole), 1818
Michaelis constant, 95
Michaelis-Menten equation, 95
Miconazole, 1587
for cutaneous fungal infection, 1818
for vaginal candidiasis, 1842t
MICRONASE (glyburide), 1257t
MICRONOR (norethindrone), 1836t
Microsomal epoxide hydrolase (mEH),
130
Microsomal triglyceride transfer
protein (MTP), 878, 882
Microsporidia, 1424
Microtubule-damaging agents, 1705
MIDAMOR (amiloride), 690–692, 690t
Midazolam
administration of, 466t
metabolism of, 128t
pharmacokinetics of, 1864t
polymorphisms and response to, 159t
therapeutic uses of, 466t
Midbrain, 364
Midodrine, 295
MIFEPREX (mifeprostone), 1837
Mifepristone, 1184–1185
as abortifacient, 1837
for postcoital contraception, 1837
risks (black box warning), 1837
in therapeutic abortion, 952
Migraine
angina pectoris with, recommended
treatment for, 769t
drug therapy for
ergot alkaloids, 347
5-HT-receptor agonists, 344–345
prophylaxis, 767
Milk of Magnesia, 1316t
Milnacipran, potencies at human
transporters for monamine
neurotransmitters, 406t
Milrinone, 771
for heart failure, 805
Miltefosine, 1430–1431
Mineral(s)
ethanol and, 638
homoestasis, 1275–1277
homoestasis disorders, 1286–1290
Mineralocorticoid receptors,
antagonists of
pharmacology of, 693t
structures of, 693t
Mineralocorticoids, regulation of gene
expression by, 1218
MINOCIN (minocycline), 1817
Minocycline, 994t
for acne, 1817
adverse effects and side effects of,
1817
pharmacokinetics of, 1865t
Minoxidil, 777
adverse effects and side effects of,
788–781, 1829
for androgenetic alopecia, 1829
as antihypertensive agent, 774t,
788–781
hypertrichosis caused by, 781
pharmacology of, 788
precautions with, 788–781
site of action of, 788
structure of, 788, 1829
therapeutic uses of, 781
topical, 1829
MIOCHOL-E (acetylcholine), 1788
Miosis, 495, 1776
Miotic agents, for glaucoma, 1788
Miproxifene, 1756
MIRCETTE (ethinyl estradiol/
desogestrel), 1835t
MIRENA, 1836
Mirtazapine
disposition of, 409t
dose and dosage forms of, 403t
pharmacokinetics of, 1865t
potencies
at human transporters for
monamine neurotransmitters,
406t
at neurotransmitter receptors, 410t
side effects of, 403t
Misoprostol
adverse effects of, 1315
for cervical ripening, 1849–1850
chemistry of, 1314
pharmacokinetics of, 1315
pharmacological properties of, 1314
for postpartum hemorrhage, 1851
for pregnancy termination, 1837
therapeutic uses of, 1315
for gastric cytoprotection, 952
in therapeutic abortion, 952
for ulcers, 1319t
Mistrust of science and industry, 11
2047
INDEX